In 2018, the Department of Trade and Industry unveiled a new policy aimed at reining in the pharmaceutical industry profiteering. But the Presidential Health Compact announced in July 2019 subtly undermines this policy. Mark Heywood and Zain Rizvi explain the arguments and the consequences.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed